Department of Dermatology, University Hospital of Asturias, Oviedo, Spain.
Australas J Dermatol. 2012 Feb;53(1):70-2. doi: 10.1111/j.1440-0960.2011.00783.x. Epub 2011 Jun 13.
Psoriatic patients have a higher prevalence of diabetes mellitus type 2 (DM). Since dipeptidyl peptidase IV (DPP-IV) dysregulation is present in DM and psoriasis, DPP-IV inhibitors have been proposed as therapeutic agents for both conditions. We report a psoriasiform eruption induced by sitagliptin, a DPP-IV inhibitor. The role of DPP-IV in the pathogenesis of DM is well established; however data on psoriatic patients is contradictory. More studies are required to elucidate the effect of DPP-IV inhibitors and their relationship with DM and psoriasis.
银屑病患者 2 型糖尿病（DM）的患病率较高。由于二肽基肽酶 IV（DPP-IV）在 DM 和银屑病中失调，因此 DPP-IV 抑制剂被提议作为这两种疾病的治疗药物。我们报告了一例由 DPP-IV 抑制剂西他列汀引起的银屑病样疹。DPP-IV 在 DM 的发病机制中的作用已得到充分证实；然而，关于银屑病患者的数据存在争议。需要更多的研究来阐明 DPP-IV 抑制剂的作用及其与 DM 和银屑病的关系。
